Clinuvel Pharmaceuticals
(ASX) CUV
Clinuvel Pharmaceuticals Financials at a Glance
Market Cap
$457.17M
Revenue (TTM)
$187.33M
Net Income (TTM)
$71.32M
EPS (TTM)
$0.64
P/E Ratio
14.03
Dividend
$0.05
Beta (Volatility)
0.15 (Low)
Dividend
$0.05
Beta (Volatility)
0.15 (Low)
Price
$9.09
Volume
118,964
Open
$9.13
Price
$9.09
Volume
118,964
Open
$9.13
Previous Close
$9.09
Daily Range
$9.00 - $9.15
52-Week Range
$8.96 - $14.00
Dividend
$0.05
Beta (Volatility)
0.15 (Low)
Price
$9.09
Volume
118,964
Open
$9.13
Previous Close
$9.09
Daily Range
$9.00 - $9.15
52-Week Range
$8.96 - $14.00
CUV News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Clinuvel Pharmaceuticals
Industry
Biotechnology
Sector
Health CareCEO
Lachlan Hay
Website
www.clinuvel.comHeadquarters
Melbourne, VIC 3000, AU
CUV Financials
Key Financial Metrics (TTM)
Gross Margin
64%
Operating Margin
39%
Net Income Margin
34%
Return on Equity
14%
Return on Capital
15%
Return on Assets
12%
Earnings Yield
7.13%
Dividend Yield
0.01%
Payout Ratio
7.70%
Stock Overview
Market Cap
$457.17M
Shares Outstanding
50.18M
Volume
118.96K
Short Interest
0.00%
Avg. Volume
114.30K
Financials (TTM)
Gross Profit
$79.14M
Operating Income
$45.73M
EBITDA
$57.20M
Operating Cash Flow
$41.10M
Capital Expenditure
$298.57K
Free Cash Flow
$40.80M
Cash & ST Invst.
$224.11M
Total Debt
$528.53K
Clinuvel Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$36.93M
+14.5%
Gross Profit
$20.75M
+22.6%
Gross Margin
56.19%
N/A
Market Cap
$457.17M
N/A
Market Cap/Employee
$28.57M
N/A
Employees
16
N/A
Net Income
$10.44M
-4.5%
EBITDA
$11.46M
-20.8%
Quarterly Fundamentals
Net Cash
$232.66M
+34.2%
Accounts Receivable
$16.58M
+26.8%
Inventory
$8.41M
-33.0%
Long Term Debt
$34.50K
-95.2%
Short Term Debt
$306.60K
-13.8%
Return on Assets
12.07%
N/A
Return on Invested Capital
15.06%
N/A
Free Cash Flow
$12.38M
-41.3%
Operating Cash Flow
$12.52M
-52.5%